0001354488-16-008247.txt : 20160901 0001354488-16-008247.hdr.sgml : 20160901 20160901200323 ACCESSION NUMBER: 0001354488-16-008247 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160901 FILED AS OF DATE: 20160901 DATE AS OF CHANGE: 20160901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TG THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001001316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 363898269 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 787 SEVENTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: (212) 554-4484 MAIL ADDRESS: STREET 1: 787 SEVENTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030310 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC DATE OF NAME CHANGE: 20000330 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WEISS MICHAEL S CENTRAL INDEX KEY: 0001038977 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32639 FILM NUMBER: 161866856 MAIL ADDRESS: STREET 1: 750 LEXINGTON AVE CITY: NEW YORK STATE: NY ZIP: 10022 4 1 issuerdirect_section16.xml PRIMARY DOCUMENT X0306 4 2016-09-01 0 0001001316 TG THERAPEUTICS, INC. TGTX 0001038977 WEISS MICHAEL S 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014 1 1 1 See Remarks Common Stock 2016-09-01 4 G 0 328764 0 D 9455662 D This Form 4 is filed by Mr. Weiss to report the transfer of 328,764 shares of TG Therapeutics stock to the Weiss Family and Descendants Trust. Includes shares of restricted Common Stock, which vest over various time periods. Includes 33,334 warrants to purchase Common Stock at $2.25, exercisable through December 31, 2016. Finally, also included in Mr. Weiss' beneficial ownership are 4,499,560 shares of Common Stock and 410,450 warrants to purchase Common Stock at $2.48, exercisable through February 24, 2017 issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest. Executive Chairman, Interim CEO and President /s/ Michael Weiss 2016-09-01